Detalhe da pesquisa
1.
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 25(6): 720-730, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740030
2.
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Lancet Oncol
; 22(7): 919-930, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051177
3.
Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
Clin Genitourin Cancer
; 14(1): e103-5, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26431887